HRP20182144T1 - Farmaceutske kompozicije koje sadrže donore nitroksila - Google Patents

Farmaceutske kompozicije koje sadrže donore nitroksila

Info

Publication number
HRP20182144T1
HRP20182144T1 HRP20182144TT HRP20182144T HRP20182144T1 HR P20182144 T1 HRP20182144 T1 HR P20182144T1 HR P20182144T T HRP20182144T T HR P20182144TT HR P20182144 T HRP20182144 T HR P20182144T HR P20182144 T1 HRP20182144 T1 HR P20182144T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical compositions
compositions containing
nitroxyl donors
containing nitroxyl
donors
Prior art date
Application number
HRP20182144TT
Other languages
English (en)
Croatian (hr)
Inventor
Vincent Jacob Kalish
John Reardon
Frederick Arthur Brookfield
Stephen Martin Courtney
Lisa Marie Frost
John P. Toscano
Original Assignee
Cardioxyl Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc. filed Critical Cardioxyl Pharmaceuticals Inc.
Publication of HRP20182144T1 publication Critical patent/HRP20182144T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20182144TT 2013-01-18 2014-01-17 Farmaceutske kompozicije koje sadrže donore nitroksila HRP20182144T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US201361782781P 2013-03-14 2013-03-14
PCT/US2014/012089 WO2014113700A1 (en) 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors
EP14703010.0A EP2945621B1 (en) 2013-01-18 2014-01-17 Pharmaceutical compositions comprising nitroxyl donors

Publications (1)

Publication Number Publication Date
HRP20182144T1 true HRP20182144T1 (hr) 2019-03-08

Family

ID=50064795

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20182144TT HRP20182144T1 (hr) 2013-01-18 2014-01-17 Farmaceutske kompozicije koje sadrže donore nitroksila
HRP20180121TT HRP20180121T1 (hr) 2013-01-18 2014-01-17 Donori nitroksila s poboljšanim terapijskim indeksom
HRP20191919TT HRP20191919T8 (hr) 2013-01-18 2019-10-23 Donori nitroksila sa poboljšanim terapijskim indeksom

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20180121TT HRP20180121T1 (hr) 2013-01-18 2014-01-17 Donori nitroksila s poboljšanim terapijskim indeksom
HRP20191919TT HRP20191919T8 (hr) 2013-01-18 2019-10-23 Donori nitroksila sa poboljšanim terapijskim indeksom

Country Status (29)

Country Link
US (13) US8987326B2 (enExample)
EP (5) EP2945621B1 (enExample)
JP (5) JP6449171B2 (enExample)
KR (2) KR102177899B1 (enExample)
CN (4) CN105142627B (enExample)
AU (5) AU2014207404B2 (enExample)
BR (2) BR112015017241B1 (enExample)
CA (2) CA2898443C (enExample)
CY (3) CY1120535T1 (enExample)
DK (3) DK2945620T3 (enExample)
ES (4) ES2882279T3 (enExample)
HK (1) HK1251170B (enExample)
HR (3) HRP20182144T1 (enExample)
HU (3) HUE046722T2 (enExample)
IL (4) IL239906B (enExample)
LT (3) LT2945621T (enExample)
MX (2) MX373176B (enExample)
NZ (4) NZ748771A (enExample)
PL (3) PL2945621T3 (enExample)
PT (3) PT2945621T (enExample)
RS (3) RS56968B1 (enExample)
RU (3) RU2684916C2 (enExample)
SG (6) SG11201505567RA (enExample)
SI (3) SI3284463T1 (enExample)
SM (3) SMT201800088T1 (enExample)
TR (1) TR201802211T4 (enExample)
TW (3) TWI686193B (enExample)
WO (2) WO2014113696A1 (enExample)
ZA (2) ZA201505090B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103435524B (zh) 2006-03-17 2016-02-10 约翰斯霍普金斯大学 作为有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物
CN104053647B (zh) 2011-10-17 2018-06-01 约翰斯霍普金斯大学 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
RS56968B1 (sr) * 2013-01-18 2018-05-31 Cardioxyl Pharmaceuticals Inc Donori nitroksila sa poboljšanim terapijskim indeksom
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
ES2749682T3 (es) 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
JP2018526448A (ja) 2015-09-07 2018-09-13 浙江華海薬業股▲フン▼有限公司 一酸化窒素を放出可能なプロドラッグ分子
WO2017070081A1 (en) 2015-10-19 2017-04-27 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
WO2017070084A1 (en) 2015-10-19 2017-04-27 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
CN110139854A (zh) 2016-07-28 2019-08-16 约翰斯霍普金斯大学 O-取代异羟肟酸
KR20190103281A (ko) * 2017-01-03 2019-09-04 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여 화합물의 투여 방법
MX393936B (es) * 2017-04-18 2025-03-24 Genfit Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico
CN116283762B (zh) * 2023-03-28 2025-08-12 昆山市第一人民医院 一种用于制备白鲜碱的中间体化合物及其制备方法、白鲜碱的制备方法
WO2025043108A1 (en) * 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
BR9506549A (pt) * 1994-01-19 1997-10-14 Byk Nederland Bv Derivados de benzilamina contendo grupos nitróxi e sua aplicação para o tratamento de enfermidades cardiovasculares bem como de pressão interna dos olhos elevada
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
CN1127492C (zh) 1997-10-24 2003-11-12 盐野义制药株式会社 抗风湿剂
SI0930302T1 (en) * 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
US6295153B1 (en) 1998-06-04 2001-09-25 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6638534B1 (en) 1998-07-28 2003-10-28 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
PT1341779E (pt) 2000-12-13 2006-10-31 Wyeth Corp Sulfonamidas heterociclicas inibidoras da producao de beta-amiloide
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
US20090281067A1 (en) 2004-01-30 2009-11-12 The John Hopkins University Nitroxyl progenitor compounds and methods of use
EP1846439A2 (en) 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
US20090298795A1 (en) 2005-06-23 2009-12-03 The Johns Hopins University Thiol-Sensitive Positive Inotropes
CN103435524B (zh) 2006-03-17 2016-02-10 约翰斯霍普金斯大学 作为有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物
AU2007238600B2 (en) 2006-04-13 2012-01-19 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
CN104119310B (zh) 2007-09-26 2017-04-12 约翰斯霍普金斯大学 作为新的在生理学上可用于硝酰基供体的n‑羟基磺酰胺衍生物及包含其的医药组合物
MX2010011924A (es) 2008-05-07 2010-11-30 Cardioxyl Pharmaceuticals Inc Nuevos compuestos nitrosos como donadores de nitroxilo y metodos de uso de los mismos.
US20110160200A1 (en) 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
IN2012DN05025A (enExample) 2009-12-07 2015-10-23 Univ Johns Hopkins
US9018411B2 (en) 2009-12-07 2015-04-28 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
CN104053647B (zh) 2011-10-17 2018-06-01 约翰斯霍普金斯大学 作为hno供体的经羟胺取代的米氏酸、巴比妥酸和吡唑啉酮衍生物
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
RS56968B1 (sr) 2013-01-18 2018-05-31 Cardioxyl Pharmaceuticals Inc Donori nitroksila sa poboljšanim terapijskim indeksom
WO2015109210A1 (en) 2014-01-17 2015-07-23 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
CA2898445C (en) 2022-05-03
ES2882279T3 (es) 2021-12-01
ES2659969T3 (es) 2018-03-20
JP2016510326A (ja) 2016-04-07
US20190224159A1 (en) 2019-07-25
US20220193026A1 (en) 2022-06-23
RU2684916C2 (ru) 2019-04-16
US9968584B2 (en) 2018-05-15
MX373176B (es) 2020-04-22
US9586896B2 (en) 2017-03-07
AU2014207408C1 (en) 2018-09-06
US11786501B2 (en) 2023-10-17
WO2014113700A9 (en) 2014-10-09
KR102177899B1 (ko) 2020-11-12
PL2945620T3 (pl) 2018-03-30
CN110179777A (zh) 2019-08-30
JP2017125015A (ja) 2017-07-20
CY1121480T1 (el) 2020-05-29
TW201446242A (zh) 2014-12-16
RU2676277C2 (ru) 2018-12-27
EP2945620A1 (en) 2015-11-25
IL259233A (en) 2018-07-31
NZ709985A (en) 2020-05-29
WO2014113696A1 (en) 2014-07-24
PL2945621T3 (pl) 2019-05-31
EP3284463A1 (en) 2018-02-21
EP3284463B1 (en) 2019-07-24
AU2018241168B2 (en) 2020-04-02
TWI619491B (zh) 2018-04-01
JP2019172682A (ja) 2019-10-10
MX363843B (es) 2019-04-05
US8987326B2 (en) 2015-03-24
EP2945620B1 (en) 2017-11-22
ZA201505090B (en) 2016-10-26
SMT201800088T1 (it) 2018-03-08
JP6449171B2 (ja) 2019-01-09
CA2898445A1 (en) 2014-07-24
EP3427728B1 (en) 2021-07-07
CY1122177T1 (el) 2020-11-25
HUE036589T2 (hu) 2018-07-30
US10213408B2 (en) 2019-02-26
AU2014207408B2 (en) 2018-03-01
NZ748769A (en) 2020-05-29
CN110179777B (zh) 2022-07-15
US12186301B2 (en) 2025-01-07
PT2945620T (pt) 2018-02-21
SG11201505567RA (en) 2015-09-29
LT3284463T (lt) 2019-11-11
RU2015134583A (ru) 2017-02-22
IL239906B (en) 2018-05-31
HUE041861T2 (hu) 2019-06-28
KR20150108879A (ko) 2015-09-30
BR112015017251A2 (pt) 2017-07-11
RS58174B1 (sr) 2019-03-29
US20200163929A1 (en) 2020-05-28
CN108610312A (zh) 2018-10-02
SG10201802855TA (en) 2018-05-30
SG10201802862WA (en) 2018-05-30
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
US11273143B2 (en) 2022-03-15
US20180235927A1 (en) 2018-08-23
US10517847B2 (en) 2019-12-31
EP3427728A1 (en) 2019-01-16
JP2016505044A (ja) 2016-02-18
JP6533159B2 (ja) 2019-06-19
US9156804B2 (en) 2015-10-13
SG10201913286PA (en) 2020-02-27
IL259233B (en) 2019-10-31
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
BR112015017241B1 (pt) 2021-10-26
PL3284463T3 (pl) 2019-12-31
MX2015009269A (es) 2015-10-30
CN105073105B (zh) 2018-02-27
SMT201900575T1 (it) 2019-11-13
TWI712409B (zh) 2020-12-11
US10548872B2 (en) 2020-02-04
WO2014113700A1 (en) 2014-07-24
JP2019089764A (ja) 2019-06-13
AU2017200147B2 (en) 2018-07-05
AU2014207404A1 (en) 2015-08-13
EP3567031A1 (en) 2019-11-13
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
US10245249B2 (en) 2019-04-02
ZA201604798B (en) 2018-01-31
SI2945621T1 (sl) 2019-01-31
TW201442702A (zh) 2014-11-16
MX2015009276A (es) 2015-10-30
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
US20210015784A1 (en) 2021-01-21
CN105142627B (zh) 2019-06-21
HRP20180121T1 (hr) 2018-02-23
JP6656345B2 (ja) 2020-03-04
NZ709986A (en) 2020-01-31
SI2945620T1 (en) 2018-01-31
HRP20191919T8 (hr) 2021-10-01
SG10201913441RA (en) 2020-03-30
TWI686193B (zh) 2020-03-01
AU2014207404B2 (en) 2017-10-19
DK3284463T3 (da) 2019-10-28
AU2018203240A1 (en) 2018-05-31
AU2018203240B2 (en) 2019-12-12
IL258882A (en) 2018-06-28
US20190133990A1 (en) 2019-05-09
ES2705240T3 (es) 2019-03-22
SI3284463T1 (sl) 2019-12-31
ES2751922T3 (es) 2020-04-02
PT3284463T (pt) 2019-10-30
IL239952A0 (en) 2015-08-31
US20150175566A1 (en) 2015-06-25
US10792273B2 (en) 2020-10-06
BR112015017241A2 (pt) 2017-07-11
PT2945621T (pt) 2019-01-21
US20240066002A1 (en) 2024-02-29
BR112015017251B1 (pt) 2021-10-26
CA2898443A1 (en) 2014-07-24
KR20150107853A (ko) 2015-09-23
HRP20191919T1 (hr) 2020-01-10
AU2018241168A1 (en) 2018-11-01
AU2014207408A8 (en) 2015-08-27
KR102277165B1 (ko) 2021-07-14
TR201802211T4 (tr) 2018-03-21
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10
AU2014207408A1 (en) 2015-08-13
CA2898443C (en) 2022-05-31
LT2945621T (lt) 2019-01-10
NZ748771A (en) 2019-12-20
RS59434B1 (sr) 2019-11-29
CN105142627A (zh) 2015-12-09
BR112015017251A8 (pt) 2019-10-29
JP6801045B2 (ja) 2020-12-16
CN105073105A (zh) 2015-11-18
DK2945620T3 (en) 2018-02-05
US20140206769A1 (en) 2014-07-24
IL239952B (en) 2018-05-31
LT2945620T (lt) 2018-02-12
IL239906A0 (en) 2015-08-31
HUE046722T2 (hu) 2020-03-30
HK1216858A1 (en) 2016-12-09
BR112015017241A8 (pt) 2019-10-29
SMT201900027T1 (it) 2019-02-28
JP6311038B2 (ja) 2018-04-11
HK1251170B (en) 2020-04-09
HK1216857A1 (en) 2016-12-09
US20170151210A1 (en) 2017-06-01
TW201934120A (zh) 2019-09-01
DK2945621T3 (en) 2019-02-11
RU2018143994A (ru) 2019-01-16

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
HRP20182144T1 (hr) Farmaceutske kompozicije koje sadrže donore nitroksila
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
EP2993213A4 (en) COMPOSITION WITH TRIFLUORETHYLENE
DK3181122T3 (da) Farmaceutisk dasatinib-sammensætning
PT3079666T (pt) Composições farmacêuticas que contêm fumarato de dimetilo
EP2889350A4 (en) ADHESIVE COMPOSITION
DK2968214T3 (da) Hidtil ukendte analgetiske sammensætninger
DK3043778T3 (da) Farmaceutiske sammensætninger, der indeholder refametinib
BR112016010669A2 (pt) composição desinfetante
DK3027750T3 (da) Biokatalytisk sammensætning
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
DK2897594T3 (da) Farmaceutisk sammensætning
HUE056943T2 (hu) CCR3 antagonistákat tartalmazó gyógyászati készítmények
IL250649A0 (en) Topical composition containing ranpirnase
DK2988733T3 (da) Farmaceutisk sammensætning indeholdende krystallin macitentan
DK3441474T3 (da) Farmaceutiske sammensætninger indeholdende et muteret leukocidin e
EP2946780A4 (en) TABLET WITH 5-HYDROXY-1H-IMIDAZOLE-4-CARBOXAMIDE
SMT201600419B (it) Composizione farmaceutica contenente fosfolipidi
HRP20182110T1 (hr) Sastav spojeva tiakumicina
PL2892528T3 (pl) Kompozycje farmaceutyczne zawierające flurbiprofen
PL2922571T3 (pl) Postać farmaceutyczna zawierająca metaloporfiryny zawierające karboran
PL2956129T3 (pl) Kompozycje farmaceutyczne zawierające deksketoprofen i tramadol
TH1501000622A (th) องค์ประกอบแชมพู
DK3082855T3 (da) Sammensætning